Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA damage response that impacts chemo- and radiotherapy responses of breast cancer.

Thakur V, Zhang K, Savadelis A, Zmina P, Aguila B, Welford SM, Abdul-Karim F, Bonk KW, Keri RA, Bedogni B.

Cancer Lett. 2019 Feb 28;443:115-124. doi: 10.1016/j.canlet.2018.11.031. Epub 2018 Nov 29.

PMID:
30502358
2.

Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells.

Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, Bar EE, Summers MK, Keri RA.

J Biol Chem. 2018 Nov 27. pii: jbc.RA118.004712. doi: 10.1074/jbc.RA118.004712. [Epub ahead of print]

3.

Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer.

Hashemi-Sadraei N, Müller-Greven GM, Abdul-Karim FW, Ulasov I, Downs-Kelly E, Burgett ME, Lauko A, Qadan MA, Weil RJ, Ahluwalia MS, Du L, Prayson RA, Chao ST, Budd TG, Barnholtz-Sloan J, Nowacki AS, Keri RA, Gladson CL.

J Neurooncol. 2018 Nov;140(2):237-248. doi: 10.1007/s11060-018-2959-5. Epub 2018 Aug 9.

PMID:
30094720
4.

A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendations.

Tsung K, Thompson CL, Knight JM, Maximuk S, Sadri N, Gilmore H, Keri RA, Vinayak S, Harris L, Silverman P.

Breast J. 2018 Jul;24(4):676-677. doi: 10.1111/tbj.13027. Epub 2018 Mar 8. No abstract available.

PMID:
29517142
5.

Targeting bromodomain and extraterminal proteins in breast cancer.

Sahni JM, Keri RA.

Pharmacol Res. 2018 Mar;129:156-176. doi: 10.1016/j.phrs.2017.11.015. Epub 2017 Nov 16. Review.

PMID:
29154989
6.

BETi induction of mitotic catastrophe: towing the LIN9.

Gayle SS, Sahni JM, Keri RA.

Oncoscience. 2017 Oct 23;4(9-10):128-130. doi: 10.18632/oncoscience.372. eCollection 2017 Sep. No abstract available.

7.

Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.

Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA.

Cancer Res. 2017 Oct 1;77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571. Epub 2017 Aug 14.

8.

Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.

Morrison CD, Chang JC, Keri RA, Schiemann WP.

Cell Death Dis. 2017 Jun 29;8(6):e2899. doi: 10.1038/cddis.2017.294.

9.

Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.

Seachrist DD, Sizemore ST, Johnson E, Abdul-Karim FW, Weber Bonk KL, Keri RA.

Breast Cancer Res. 2017 Jun 5;19(1):66. doi: 10.1186/s13058-017-0857-y.

10.

Regulatory cross-talk determines the cellular levels of 53BP1 protein, a critical factor in DNA repair.

Mayca Pozo F, Tang J, Bonk KW, Keri RA, Yao X, Zhang Y.

J Biol Chem. 2017 Apr 7;292(14):5992-6003. doi: 10.1074/jbc.M116.760645. Epub 2017 Mar 2.

11.

Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome.

Cohen AJ, Saiakhova A, Corradin O, Luppino JM, Lovrenert K, Bartels CF, Morrow JJ, Mack SC, Dhillon G, Beard L, Myeroff L, Kalady MF, Willis J, Bradner JE, Keri RA, Berger NA, Pruett-Miller SM, Markowitz SD, Scacheri PC.

Nat Commun. 2017 Feb 7;8:14400. doi: 10.1038/ncomms14400.

12.

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.

Sahni JM, Gayle SS, Bonk KL, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA.

J Biol Chem. 2016 Nov 4;291(45):23756-23768. Epub 2016 Sep 20.

13.

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.

Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP.

Oncotarget. 2016 Nov 8;7(45):72777-72794. doi: 10.18632/oncotarget.11909.

14.

Bioengineering of Tobacco Mosaic Virus to Create a Non-Infectious Positive Control for Ebola Diagnostic Assays.

Lam P, Gulati NM, Stewart PL, Keri RA, Steinmetz NF.

Sci Rep. 2016 Mar 31;6:23803. doi: 10.1038/srep23803.

15.

Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer.

Yehia L, Niazi F, Ni Y, Ngeow J, Sankunny M, Liu Z, Wei W, Mester JL, Keri RA, Zhang B, Eng C.

Am J Hum Genet. 2015 Nov 5;97(5):661-76. doi: 10.1016/j.ajhg.2015.10.001. Epub 2015 Oct 29.

16.

A review of the carcinogenic potential of bisphenol A.

Seachrist DD, Bonk KW, Ho SM, Prins GS, Soto AM, Keri RA.

Reprod Toxicol. 2016 Jan;59:167-82. doi: 10.1016/j.reprotox.2015.09.006. Epub 2015 Oct 19. Review.

17.

UbcH7 regulates 53BP1 stability and DSB repair.

Han X, Zhang L, Chung J, Mayca Pozo F, Tran A, Seachrist DD, Jacobberger JW, Keri RA, Gilmore H, Zhang Y.

Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17456-61. doi: 10.1073/pnas.1408538111. Epub 2014 Nov 24.

18.

Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.

Yori JL, Lozada KL, Seachrist DD, Mosley JD, Abdul-Karim FW, Booth CN, Flask CA, Keri RA.

Cancer Res. 2014 Sep 1;74(17):4762-71. doi: 10.1158/0008-5472.CAN-13-3627. Epub 2014 Jul 14.

19.

GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2).

Sizemore GM, Sizemore ST, Seachrist DD, Keri RA.

J Biol Chem. 2014 Aug 29;289(35):24102-13. doi: 10.1074/jbc.M114.593582. Epub 2014 Jul 10.

20.

Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.

Sizemore ST, Sizemore GM, Booth CN, Thompson CL, Silverman P, Bebek G, Abdul-Karim FW, Avril S, Keri RA.

Breast Cancer Res Treat. 2014 Jul;146(1):25-40. doi: 10.1007/s10549-014-2989-4. Epub 2014 May 22.

Supplemental Content

Loading ...
Support Center